Total Payments
$354.92
2023 Payments
$98.80
Companies
12
Transactions
16
Medicare Patients
4,367
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$282.92 (79.7%)
Education$72.00 (20.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $282.92 | 15 | 79.7% |
| Education | $72.00 | 1 | 20.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Products, LP | $72.00 | 1 | $0 (2019) |
| Merck Sharp & Dohme LLC | $64.39 | 4 | $0 (2022) |
| Baxter Healthcare | $37.26 | 1 | $0 (2023) |
| Mylan Institutional Inc. | $32.09 | 2 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $24.44 | 1 | $0 (2023) |
| PFIZER INC. | $23.33 | 1 | $0 (2023) |
| TETRAPHASE PHARMACEUTICALS, INC. | $22.22 | 1 | $0 (2019) |
| Smith+Nephew, Inc. | $19.28 | 1 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $16.42 | 1 | $0 (2019) |
| GENZYME CORPORATION | $15.20 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $98.80 | 4 | Baxter Healthcare ($37.26) |
| 2022 | $72.97 | 4 | Merck Sharp & Dohme LLC ($38.49) |
| 2019 | $157.25 | 6 | Janssen Products, LP ($72.00) |
| 2018 | $14.19 | 1 | Merck Sharp & Dohme Corporation ($14.19) |
| 2017 | $11.71 | 1 | Merck Sharp & Dohme Corporation ($11.71) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/22/2023 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: IMMUNOLOGY | ||||||
| 06/28/2023 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 02/20/2023 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $37.26 | General |
| Category: Airway Clearance Device | ||||||
| 01/10/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Rare Disease | ||||||
| 12/06/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: Immunology | ||||||
| 10/05/2022 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA, RECARBRIO | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/15/2022 | Smith+Nephew, Inc. | STRAVIX (Medical Supply) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: Extremities & Limb Restoration | ||||||
| 03/17/2022 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/17/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 09/16/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/24/2019 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Respiratory | ||||||
| 05/08/2019 | Mylan Institutional Inc. | Cimduo (Drug), Symfi, Symfi Lo | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Infectious Disease | ||||||
| 01/23/2019 | Mylan Institutional Inc. | Cimduo (Drug), Symfi, Symfi Lo | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Infectious Disease | ||||||
| 01/03/2019 | Janssen Products, LP | PREZCOBIX (Drug) | Education | In-kind items and services | $72.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 01/23/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/09/2017 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA, SIVEXTRO | Food and Beverage | In-kind items and services | $11.71 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 879 | 2,949 | $385,711 | $218,007 |
| 2022 | 7 | 1,130 | 3,870 | $497,294 | $262,278 |
| 2021 | 8 | 1,159 | 4,673 | $602,764 | $325,174 |
| 2020 | 9 | 1,199 | 4,809 | $631,870 | $344,949 |
Total Patients
4,367
Total Services
16,301
Medicare Billing
$1.2M
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 338 | 1,594 | $165,821 | $95,882 | 57.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 135 | 862 | $128,438 | $78,708 | 61.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 273 | 323 | $63,954 | $31,224 | 48.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 91 | $12,194 | $5,649 | 46.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 26 | $7,566 | $3,371 | 44.6% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 51 | 53 | $7,738 | $3,172 | 41.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 434 | 2,256 | $234,624 | $124,236 | 53.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 233 | 1,088 | $162,112 | $85,974 | 53.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 353 | 389 | $77,022 | $40,076 | 52.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 50 | $9,550 | $4,740 | 49.6% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 33 | 37 | $5,402 | $2,879 | 53.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 38 | $5,092 | $2,507 | 49.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $3,492 | $1,867 | 53.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 408 | 2,700 | $280,699 | $152,017 | 54.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 249 | 1,400 | $208,600 | $112,933 | 54.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 341 | 375 | $74,250 | $39,744 | 53.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 53 | 83 | $15,757 | $8,136 | 51.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 44 | 47 | $13,677 | $7,383 | 54.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 32 | 36 | $4,749 | $2,251 | 47.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 20 | 20 | $3,280 | $1,755 | 53.5% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 12 | 12 | $1,752 | $954.96 | 54.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 316 | 1,815 | $270,435 | $148,973 | 55.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 340 | 2,370 | $244,110 | $134,400 | 55.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 364 | 411 | $81,378 | $43,871 | 53.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 57 | 74 | $11,766 | $5,738 | 48.8% |
About Dr. Luis Jauregui, M.D
Dr. Luis Jauregui, M.D is a Infectious Disease healthcare provider based in Toledo, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1578554242.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Luis Jauregui, M.D has received a total of $354.92 in payments from pharmaceutical and medical device companies, with $98.80 received in 2023. These payments were reported across 16 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($282.92).
As a Medicare-enrolled provider, Jauregui has provided services to 4,367 Medicare beneficiaries, totaling 16,301 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Toledo, OH
- Active Since 11/02/2005
- Last Updated 01/26/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1578554242
Products in Payments
- PREZCOBIX (Drug) $72.00
- Hillrom - Vest System Model 105 Home Care (Device) $37.26
- Cimduo (Drug) $32.09
- ULTOMIRIS (Biological) $24.44
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug) $23.33
- Xerava (Drug) $22.22
- DELSTRIGO (Drug) $22.21
- STRAVIX (Medical Supply) $19.28
- XARELTO (Drug) $16.42
- DIFICID (Drug) $16.28
- DUPIXENT (Biological) $15.20
- Arikayce (Drug) $14.52
- ZERBAXA (Drug) $14.19
- XERAVA (Drug) $13.77
- CUBICIN RF (Drug) $11.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Toledo
Tanyanyiwa Chinyadza, M.d, M.D
Infectious Disease — Payments: $7,405
Infectious Disease $7,405
Dr. Arlette Aouad, M.d, M.D
Infectious Disease — Payments: $1,645
Infectious Disease $1,645
Dr. Caitlyn Hollingshead, Md, MD
Infectious Disease — Payments: $332.90
Infectious Disease $332.90
Razi Syed, Md, MD
Infectious Disease — Payments: $283.43
Infectious Disease $283.43
Michael Ellis, M.d, M.D
Infectious Disease — Payments: $85.64
Infectious Disease $85.64
Dr. Haig Donabedian, M.d, M.D
Infectious Disease
Infectious Disease